Silex Quantum Silicon Production Plant Update – Construction Completed, Commissioning Underway

29 June 2026

Silex Systems Limited (**Silex** or the **Company**) (**ASX: SLX; OTCQX: SILXY**) is pleased to advise that it has completed construction of the world's first laser-based silicon enrichment plant (the "SILEX Quantum Silicon (**Q-Si**) Production Plant") at its facility in Sydney, Australia.

Enriched silicon-28 in the form of high-purity Q-Si is required for next-generation silicon-based quantum computers being developed by advanced semiconductor companies around the world. Quantum computers, the first of which are expected to be commercialised by the end of the decade, could revolutionise the computing industry by providing an immense increase in computing power, compared to today's most advanced classical chips made by companies such as Nvidia, Intel, IBM and AMD. Quantum computing is therefore expected to underpin a transformational performance uplift in the emerging Artificial Intelligence (**AI**) industry.

Michael Goldsworthy, Silex's CEO/Managing Director said:

"We are excited about our upcoming entry into the critical supply chain for silicon-based quantum computing and providing a vital strategic material in the form of highly enriched Q-Si. Quantum computing promises to provide an exponential increase in computing power over classical computing, and will effectively turbo-charge AI and the key fields and industries which are being transformed by AI. Quantum computing is emerging as a critical strategic technology globally, into which governments and corporates, including leading semiconductor companies and hyperscalers, are investing billions of dollars annually. Accordingly, there is strong market desire for a new resilient Western supply source for high purity enriched silicon."

Activities in Silex's Q-Si Production Project are currently focused on the functional integration of the plant laser system and the first two silicon enrichment reactors, before final plant commissioning activities are undertaken later this calendar year. Sample production of highly enriched silicon-28 is expected to commence in Q1 CY2027. The initial Q-Si production module will produce up to 20kg of Q-Si annually (depending on several factors, such as market demand and customer purity requirements), which will be converted into gaseous and solid product forms, as required by various customers around the world.

Potential expansion of modular production capacity at a new dedicated site could occur over the coming years as market demand grows. Internal market analysis indicates the current market is small (less than 50 kgs per year); however, we expect this market to expand significantly over the next five to 10 years. Historically, enriched silicon was primarily sourced from Russia, which uses gas centrifuge technology for production.

Silex Systems Limited | ABN 69 003 372 067
LHSTC, New Illawarra Road, Lucas Heights NSW 2234
Telephone: +61 2 9704 8888 | Facsimile: +61 2 9704 8851 | Website: www.silex.com.au

Q-Si products can be used by silicon-based quantum computing developers as the substrate material for the fabrication of qubits – the building blocks of quantum computers, akin to transistor devices in classical silicon chips, but on a much smaller atomic scale. Silex is currently working with its first commercial offtake partner, Silicon Quantum Computing Pty Ltd, to qualify Q-Si products with the highest possible isotopic and chemical purity. Furthermore, increasing levels of engagement with several other potential customers offshore is expected to result in additional product offtake arrangements being concluded over the next year and beyond.

Authorised for release by the Silex Board of Directors.

Further information on the Company's activities can be found on the Silex website: www.silex.com.au or by contacting:

Michael Goldsworthy
CEO/Managing Director
T +61 2 9704 8888
E investor.relations@silex.com.au

Julie Russell
CFO/Company Secretary
T +61 2 9704 8888
E investor.relations@silex.com.au

Important Information:

About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY)

Silex Systems Limited ABN 69 003 372 067 (**Silex** or **Company**) is a technology commercialisation company, the primary asset of which is the SILEX laser enrichment technology (**SILEX technology**), originally developed at the Company's technology facility in Sydney, Australia. The SILEX technology has been under development for uranium enrichment jointly with US-based exclusive licensee, Global Laser Enrichment LLC (**GLE**), for a number of years. Success of the SILEX uranium enrichment technology development program and the proposed Paducah commercial project remain subject to a number of factors, including the satisfactory completion of the SILEX technology maturation program, nuclear fuel market conditions, industry and government support, project feasibility, and commercial plant licensing, and, therefore, remains subject to associated risks.

Silex also is at various stages of development of additional commercial applications of the SILEX technology, including the production of 'Quantum Silicon' (**Q-Si**) for the emerging technology of silicon-based quantum computing. The Q-Si Project remains dependent on the outcomes of the Project, as well as the successful development of silicon-based quantum computing technology by third parties, and is, therefore, subject to various risks. Silex also is conducting early-stage research activities in its Medical Isotope Separation Technology (**MIST**) Project, which also is subject to various risks and outcomes. The commercial future of the SILEX technology in application to uranium, silicon, medical, and other isotopes therefore is uncertain, and any plans for commercial deployment are speculative.

Forward Looking Statements

The commercial potential of the abovementioned technologies and activities is currently unknown. Accordingly, no guarantees as to the future performance of these technologies can be made. The nature of the statements in this Announcement regarding the future of the SILEX technology as applied to uranium enrichment, Q-Si production, medical and other isotope separation projects, and any associated commercial prospects, including technology maturation activities and other commercialisation milestones at GLE, are forward-looking and are subject to a number of variables, including, but not limited to, known and unknown risks, contingencies, and assumptions that may be beyond the control of Silex, its directors, and management. You should not place reliance on any forward-looking statements as actual results could be materially different from those expressed or implied by such forward-looking statements, as a result of various risk factors. Further, the forward-looking statements contained in this disclosure involve subjective judgement and analysis and, accordingly, are subject to: change at any time due to variations in the outlook for, and management of, Silex's business activities (including project outcomes); changes in industry trends and government policies; and new or unforeseen circumstances. The Company's management believes that there are reasonable grounds to make such statements as at the date of this disclosure. Silex does not intend, and is not obligated, to update the forward-looking statements except to the extent required by law or the ASX Listing Rules. None of Silex, its related companies, or any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents, or advisers makes any representation or warranty as to the accuracy of any forward-looking statements contained in this Announcement.

Not Advice

Information in this Announcement, including forecast financial information, should not be considered as investment, legal, tax, or other advice. You should make your own assessment and seek independent professional advice in connection with any investment decision.

Risk Factors

Risk factors that could affect the future results and commercial prospects of Silex include, but are not limited to: ongoing economic and social uncertainty, including in relation to global economic stresses, such as interest rates; inflation; tariffs (including tariffs imposed by the United States); geopolitical risks, in particular, those relating to Russia's invasion of Ukraine and tensions between China and Taiwan, which may affect global supply chains and capital markets; uncertainties related to the effects of climate change and mitigation efforts; the results of the GLE/SILEX uranium enrichment technology maturation program; the market demand for natural uranium and enriched uranium; the outcome of the Q-Si Project for the production of enriched silicon for the emerging silicon-based quantum computing industry; the outcome of the MIST Project; the potential development of, or competition from, alternative technologies; the regulatory changes and uncertainties related to various US Government funding initiatives, the potential for third party claims against the Company's ownership of Intellectual Property; the potential impact of prevailing laws or government regulations or policies in the US, Australia, or elsewhere; actions taken by the Company's commercialisation partners and other stakeholders that could adversely affect the technology development programs and commercialisation strategies of Silex; and the outcomes of various strategies and projects undertaken by the Company.